In anaplastic thyroid carcinoma cells, the combination of apigenin and TRAIL resulted in a decreased BCL2 and increased ERK1 and ERK2 expression [34]. The gene discussed is MAPK3; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.